Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

729
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
729
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

756
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
756
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

650
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
650
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

773
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
773
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).

Diabetes, obesity & metabolism·2026
Same author

Serum adipocytokine levels in patients with renal cell carcinoma.

Endokrynologia Polska·2026
Same author

Lipidogram profiles in patients with Graves' and Basedow's disease with and without orbitopathy.

Endokrynologia Polska·2026
Same author

Is vitamin D deficiency a risk factor for obesity-related morbidity, prediabetes, and type 2 diabetes - a literature review and proposals from the experts of the Polish Society of Endocrinology.

Endokrynologia Polska·2025
Same author

The Influence of the Type of Metal-on-Metal Hip Endoprosthesis on the Clinical, Biochemical, and Oxidative Balance Status-A Comparison of Resurfacing and Metaphyseal Implants.

Nanomaterials (Basel, Switzerland)·2025
Same author

Sarcoidosis unmasked by Cushing's syndrome: successful surgical resolution.

Archives of medical science : AMS·2025

Related Experiment Video

Updated: Feb 24, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Metformin - a new old drug.

Marta Patrycja Wróbel1, Bogdan Marek, Dariusz Kajdaniuk

  • 1Department of Internal Medicine, Diabetology and Cardiometabolic Disorders, School of Medicine with the Division of Dentistry in Zabrze,Medical University of Silesia, Zabrze, Poland. mwrobel@sum.edu.pl.

Endokrynologia Polska
|August 19, 2017
PubMed
Summary

Metformin is a first-line type 2 diabetes drug that lowers blood glucose by inhibiting liver glucose production and increasing insulin sensitivity. It also offers cardioprotective and potential anti-cancer benefits.

Keywords:
metforminmetformin propertiestype 2 diabetes

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Experiment Videos

Last Updated: Feb 24, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Metformin is the established first-line treatment for type 2 diabetes mellitus.
  • It is recommended for monotherapy and combination therapy with other antidiabetic agents.
  • Metformin exhibits pleiotropic effects beyond glycemic control, expanding its therapeutic scope.

Purpose of the Study:

  • To provide a comprehensive overview of metformin's properties, mechanisms of action, and clinical effects.
  • To discuss the expanded indications for metformin, including prediabetes and polycystic ovary syndrome.
  • To elucidate the cellular mechanisms underlying metformin's therapeutic actions.

Main Methods:

  • Review of existing literature on metformin's pharmacology and clinical applications.
  • Analysis of studies investigating metformin's cellular and molecular mechanisms.
  • Discussion of metformin's pleiotropic effects and potential adverse interactions.

Main Results:

  • Metformin lowers blood glucose by reducing hepatic glucose production and enhancing peripheral insulin sensitivity.
  • It is weight-neutral, cardioprotective, improves lipid profiles, and may possess anti-cancer properties.
  • Metformin accumulation in the intestinal mucosa can affect FDG-PET-CT imaging.

Conclusions:

  • Metformin remains a cornerstone in type 2 diabetes management with diverse beneficial effects.
  • Understanding its detailed mechanisms of action enhances its clinical application and exploration of new therapeutic uses.
  • Further research is warranted to fully characterize its pleiotropic activities and optimize its use.